Diosmin
CAS 520-27-4
Diosmin (CAS 520-27-4) is a Phase 4 pharmaceutical compound with 2 bioactivity targets and 1,854 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 29219.121875 nM | 32 | - |
| - | Potency | 27848.647619047617 nM | 21 | - |
| - | IC50 | 53490 nM | 8 | - |
| - | IC50 | 19.97 ug.mL-1 | 1 | - |
| - | MIC | 32 ug.mL-1 | 1 | - |
| Inhibitor of nuclear factor kappa-B kinase subunit beta Kinase |
IC50 | 5.41 | - | Homo sapiens |
| Lysine-specific histone demethylase 1A Enzyme |
IC50 | 4.99 | - | Homo sapiens |
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Blood lactic acid | 14 | 89.433 | 10005632 |
| Tubulointerstitial nephritis and uveitis syndrome | 11 | 70.045 | 10069034 |
| Erysipelas | 19 | 63.735 | 10015145 |
| Hypercapnia | 13 | 42.394 | 10020591 |
| Myoglobin blood increased | 10 | 37.219 | 10028625 |
| Ventricular tachycardia | 18 | 37.178 | 10047302 |
| Lentigo maligna | 6 | 30.881 | 10024218 |
| Delirium | 20 | 29.738 | 10012218 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| DIOSMIN | 3489 | SU | MTHSPL |
| diosmin | 3489 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Diosmin used for in pharmaceutical contexts?
Diosmin (CAS 520-27-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Diosmin?
Diosmin has 1,854 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Blood lactic acid, Tubulointerstitial nephritis and uveitis syndrome, Erysipelas, Hypercapnia, Myoglobin blood increased. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Diosmin also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Diosmin with EU status "permitted".
What clinical phase is Diosmin in?
Diosmin is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Diosmin?
Diosmin has 7 bioactivity rows in this page query. Rendered target entries include Inhibitor of nuclear factor kappa-B kinase subunit beta, Lysine-specific histone demethylase 1A.